+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Exenatide"

From
Peptide Based Metabolic Disorder Therapeutic Market in Saudi Arabia - Product Thumbnail Image

Peptide Based Metabolic Disorder Therapeutic Market in Saudi Arabia

  • Report
  • May 2026
  • 150 Pages
  • Saudi Arabia
From
Peptide Based Metabolic Disorder Therapeutic Market in South Africa - Product Thumbnail Image

Peptide Based Metabolic Disorder Therapeutic Market in South Africa

  • Report
  • May 2026
  • 150 Pages
  • South Africa
From
Peptide Based Metabolic Disorder Therapeutic Market in South Korea - Product Thumbnail Image

Peptide Based Metabolic Disorder Therapeutic Market in South Korea

  • Report
  • May 2026
  • 150 Pages
  • South Korea
From
From
From
From
From
Loading Indicator

Exenatide is a drug used to treat endocrine and metabolic disorders. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to regulate glucose levels in the body. Exenatide is used to treat type 2 diabetes, and is administered as a subcutaneous injection. It works by stimulating the release of insulin from the pancreas, and by slowing the rate of glucose absorption from the gastrointestinal tract. Exenatide is available in two forms: a long-acting version (Bydureon) and a short-acting version (Byetta). Both versions are used to improve glycemic control in adults with type 2 diabetes, and can be used in combination with other diabetes medications. Exenatide has been shown to reduce the risk of cardiovascular events in patients with type 2 diabetes. Exenatide is marketed by several companies, including AstraZeneca, Eli Lilly, and Novo Nordisk. It is also available as a generic drug in some countries. Show Less Read more